Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study

Objective: to analyze the frequency of metastasectomy in general population of patients with RAS wild-type metastatic colorectal cancer who received chemotherapy and anti-EGFR monoclonal antibodiesMaterials and methods. This prospective, non-randomized, multicenter study was designed to evaluate the...

Full description

Bibliographic Details
Main Authors: M. Yu. Fedyanin, L. Yu. Vladimirova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, E. A. Kalabanova, Е. G. Panina, A. I. Arzamastseva, E. G. Rybakov, L. V. Bolotina, T. V. Ustinova, А. А. Kachmazov, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh. Kh.-M. Elsnukaeva, D. V. Podluzhniy, S. A. Tjulandin, O. I. Kit
Format: Article
Language:Russian
Published: “ABV-press” Publishing house”, LLC 2019-06-01
Series:Тазовая хирургия и онкология
Subjects:
colorectal cancer
metastasectomy
anti-egfr monoclonal antibodies
cetuximab
panitumumab
chemotherapy
Online Access:https://ok.abvpress.ru/jour/article/view/284

Internet

https://ok.abvpress.ru/jour/article/view/284

Similar Items